Tagribo 80 mg (Tablet)
Unit Price: ৳ 425.00 (3 x 10: ৳ 12,750.00)
Strip Price: ৳ 4,250.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Osimertinib |
| Company | Techno drugs ltd |
Title
- Tagribo Tablets
Categories
- Cancer Treatment
- Pharmacology
- Dosage & Administration
- Drug Interaction
- Side Effects
- Pregnancy & Lactation
- Precautions & Warnings
- Special Populations
- Therapeutic Class
- Storage Conditions
Description
- Tagribo is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
- Osimertinib is a kinase inhibitor that binds irreversibly to mutant forms of EGFR, exhibiting anti-tumor activity against NSCLC lines harboring EGFR mutations.
- The recommended dose of Osimertinib is an 80 mg tablet once a day until disease progression or unacceptable toxicity.
- Avoid concomitant administration of Tagribo with strong CYP3A inhibitors or inducers, and with drugs that are sensitive substrates of CYP3A, breast cancer resistance protein (BCRP), or CYP1A2 with narrow therapeutic indices.
- Common adverse reactions include diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue, and decreased appetite.
- Osimertinib can cause fetal harm when administered to a pregnant woman, and may impair fertility in females and males of reproductive potential.
- Precautions include monitoring for interstitial lung disease (ILD)/pneumonitis, QTc interval prolongation, and cardiomyopathy, along with advising effective contraception during treatment.
- No clinically significant differences in the pharmacokinetics of Tagribo were observed based on age, sex, ethnicity, body weight, renal or hepatic impairment, and no pediatric use has been established.
- Tagribo belongs to the therapeutic class of cytotoxic chemotherapy, and should be stored below 30°C, protected from moisture & light, and kept out of the reach of children.